GLP-1s and dementia: what the Alzheimer's trials found
evoke and evoke+ were built to test whether semaglutide slows Alzheimer's disease. They reported in The Lancet in 2026.
Do GLP-1 drugs prevent or slow dementia?
Not on the evidence of the trials designed to find out. evoke and evoke+ randomised 3,808 people with early-stage symptomatic Alzheimer's disease to oral semaglutide 14 mg or placebo for 104 weeks. Decline on the standard clinical scale, the CDR-SB, was the same in both arms: 2.3 points with semaglutide and 2.3 with placebo in evoke, 2.2 and 2.1 in evoke+. The authors concluded it was not efficacious in slowing progression.
That is a result for people who already had symptoms, on one drug in tablet form. It does not test prevention in people without symptoms, and it does not test tirzepatide or the injections. No GLP-1 label mentions dementia or cognition as a use. The one weight-loss label with a cognitive warning is Qsymia's, because of topiramate.
Last updated 2026-09-02 — the newest FDA label version quoted below. Read and dated by Alex Seot.
The one cognitive warning on a weight-loss label
Not a GLP-1. Quoted because it is the label people usually mean when they ask whether a weight-loss drug affects memory.
Cognitive impairment, from topiramate
“QSYMIA can cause cognitive dysfunction (e.g., impairment of concentration/attention, difficulty with memory, and speech or language problems, particularly word-finding difficulties). Rapid titration or high initial doses of QSYMIA may be associated with higher rates of cognitive events such as attention, memory, and language/word-finding difficulties”
Labels that say nothing on it
No GLP-1 label on this site mentions dementia:
The trials
3,808 participants with early-stage symptomatic Alzheimer's disease, mean age 72, randomised to oral semaglutide 14 mg (flexible dose) or placebo for 104 weeks. Change in CDR-SB: 2.3 against 2.3 in evoke (difference −0.08, 95% CI −0.35 to 0.20) and 2.2 against 2.1 in evoke+ (0.10, −0.17 to 0.38). Not efficacious in slowing progression; safety consistent with other indications.
GLP-1s and dementia, answered
- Is semaglutide approved for Alzheimer's?
- No. The evoke trials were the attempt to show it slows the disease, and neither found a difference from placebo.
- Does the result apply to Ozempic or Wegovy injections?
- Not directly. The trials used the 14 mg tablet, the top Rybelsus dose. The injections and higher doses were not tested in them, so the question for those is untested rather than answered.
- Can weight-loss drugs affect memory?
- Qsymia's label warns of cognitive problems — concentration, memory and word-finding — from its topiramate, more so with fast titration. No GLP-1 label carries a cognitive warning.